Document is current
Any future updates will be listed below
-
Authors
Adiprakoso, Dhirendra
Katsimpokis, Dimitris
Oerlemans, Simone
Ezendam, Nicole P. M.
van Maaren, Marissa C.
van Til, Janine A.
van der Heijden, Thijs G. W.
Mols, Floortje
Aben, Katja K. H.
Vink, Geraldine R.
Koopman, Miriam
van de Poll-Franse, Lonneke V.
de Rooij, Belle H. https://orcid.org/0000-0002-0172-0857
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (UVT 2010-4743, UVA 2013-6331, 2013-5942, IKNL 2015–7914)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (2016/04981/ZONMW-91101002)
- License Information
-
More Information
Article History
Accepted: 3 October 2024
First Online: 9 November 2024
Declarations
:
: MK reports having an advisory role for Eisai, Nordic Farma, Merck-Serono, Pierre Fabre, Servier; Institutional scientific grants from Bayer, Bristol Myers Squibb, Merck, Personal Genome Diagnostics (PGDx), Pierre Fabre, Roche, Sirtex, Servier. MK is principal investigator of the international cohort study PROMETCO with Servier as sponsor.
: Ethical approval was previously obtained for each study cohort separately (ROGY: NL33429.008.10 []; PROCORE: NL51119.060.14; PLCRC: NL47888.041.14. []). Both the BlaZIB and ProZIB studies [, ] were beyond the scope of the Medical Research Involving Human Subjects Act (WMO) and, therefore, an ethics approval was waived.
: Informed consent was obtained from all individual participants included in the study.
